reports
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of...
Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints LONDON, Ontario and BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today provided an update on its ongoing clinical trial in patients with T1D...
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Devel...
Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D Dr. Calias to add Operational Depth and Cell Therapy Expertise to Sernova LONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the appointment of Pericles (Perry) Calias, Ph.D., as Chief Development Officer (CDO) and Head of R&D. Dr. Calias brings over ...
Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing
Sernova Biotherapeutics Secures $1 Million Convertible Debt Financing LONDON, Ontario and BOSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced a CAD$1,000,000 unsecured convertible debenture financing with Dr. Steven Sangha, a current Sernova shareholder and board member. Proceeds from the financing will be used to fund working capital. The debenture is repayable on March 4, 2027,...
Sernova Biotherapeutics Receives FDA Clearance for IND Application for...
Sernova Biotherapeutics Receives FDA Clearance for IND Application for its Cell Pouch Bio-hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism LONDON, Ontario and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (FDA) has cleared it’s Investigational New Drug (IND) application to evaluate the Company’s Cell Pouch ...
Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio...
Sernova Biotherapeutics Submits IND Application for its Cell Pouch Bio-Hybrid Organ with Autograft Thyroid Cells in Patients with Hypothyroidism LONDON, Ontario and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate the Company’s Cell Pouch auto-transplanted...
Sernova Announces Appointment of Ross Haghighat as Chair of the Board ...
Sernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova Biotherapeutics LONDON, Ontario and BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), today announced the appointment of Ross Haghighat as Chair of the Board. With a proven track record in driving successful innovations, strategic growth and mergers and acquisitions in the biotechnology an...
Sernova Announces Voting Results from its Annual and Special General M...
Sernova Announces Voting Results from its Annual and Special General Meeting of Shareholders LONDON, Ontario and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced results from its annual and special general meeting of shareholders (the “Meeting”) held virtually via live audio webcast on January 10, 2025. At the Meeting, a total of 74,190,067 common shares were voted, representing 22.8% of t...
Sernova Reschedules its Annual General and Special Meeting of Sharehol...
Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025 LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that it will hold its annual general and special meeting of shareholders (the “Meeting”) on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal strike in Canada, the Meeting, which had originally been scheduled to b...
Sernova Update on Strategic Initiatives
Sernova Update on Strategic Initiatives Signed Letter of Intent with ‘Project REEM Ventures’ for Product Development and Commercialization in the Kingdom of Saudi Arabia Renowned Diabetes Expert Dr. Robert Gabbay to Serve as Clinical Advisor Town Hall Call to be Held on December 13; AGM Circular Available on December 6 LONDON, Ontario and BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced...
Sernova Announces New Positive Data from Phase I/II Trial Regarding Is...
Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantationHistological data confirmation of healthy beta, alpha and delta cells secreting insulin, glucagon, and somatostatin in all Cell Pouch ChambersSernova’s Cell Pouch safely contains its therapeutic cells and provides full retrievability using conventional instruments and methodsPathology confirmed no evidence of detrimental fibrotic tissue associa...
Sernova Corp. Announces Appointment of New Chief Executive Officer
Sernova Corp. Announces Appointment of New Chief Executive Officer LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company’s new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, ...
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations f...
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for th...
Sernova Announces New Advancements of Conformal Coating Technology in ...
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coating immune protection technology program, that is used in combination with the Cell Pouch™. The goal of the program is to eliminate the need for chronic immunosuppression medications, currently used in isl...
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for...
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years;5 of 6 patients in Cohort A discontinued insulin therapy (insulin independent) following islet transplantation into the Cell Pouch and modest islet top-up via portal vein. All 6 patients achieved HbA1c values in the non-diabetic range (
Sernova to Provide Two Program Updates in Podium Presentations at 2023...
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress Dr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) Dr. Alice Tomei presenting preclinical data on transplantation of conformal coated islet cells in pre-vascularized Cell Pouch LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced two oral presentations at the up...
EQS-News: Sernova-Telefonkonferenz für Investoren, die ursprünglich fü...
Emittent / Herausgeber: Sernova Corp. / Schlagwort(e): Konferenz/Sonstiges Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben 14.09.2023 / 22:06 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. LONDON, ONTARIO und WINDHAM COUNTY, CONNECTICUT, den 14. September 2023 - Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FWB/XETRA:PSH), ein Unternehmen im klinischen Stadium und Marktführer für Zelltherapeutika, gab heute bekannt, dass die ursprünglich für den 15. Septe...
EQS-News: Sernova Investor Conference Call Previously Scheduled for Se...
Issuer: Sernova Corp. / Key word(s): Conference/Miscellaneous Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22 14.09.2023 / 22:06 CET/CEST The issuer is solely responsible for the content of this announcement. LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 14, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern...
Sernova Investor Conference Call Previously Scheduled for September 15...
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22 LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on September 22 at 10 a.m. Eastern Time. The business strategy and update call remains as scheduled for October 5, 2023. This call will ...
EQS-News: Sernova veranstaltet Telefonkonferenzen für Investoren zur V...
Emittent / Herausgeber: Sernova Corp. / Schlagwort(e): Konferenz/Sonstiges Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung 13.09.2023 / 13:01 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. - Vorstellung der neuen CEO Cynthia Pussinen und des kürzlich ernannten Chief Business Officer, Dr. Modestus Obochi, am 15. September 2023 - Telefonkonferenz zu Geschäftsentwicklung, Strategie und Ausblick am 5. Oktober 2023 LONDON, ONTARIO und...
EQS-News: Sernova to Host Investor Calls to Introduce Newly Appointed ...
Issuer: Sernova Corp. / Key word(s): Conference/Miscellaneous Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update 13.09.2023 / 13:01 CET/CEST The issuer is solely responsible for the content of this announcement. - Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 - - Business Update, Strategy & Outlook Call on October 5, 2023 - LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 13, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.